Background Risk stratification or progression in prostate cancer is performed with the
support of clinical-pathological data such as the sum of the Gleason score and serum levels …

Background Castration-resistant prostate cancer (CRPC) occurs when prostate cancer
(CaP) progresses under therapy-induced castrate conditions. Several mechanisms have …

Resistance to androgen receptor (AR) blockade in castration-resistant prostate cancer
(CRPC) is associated with sustained AR signaling, including through alternative splicing of …

BACKGROUND. Liquid biopsies have demonstrated that the constitutively active androgen
receptor splice variant-7 (AR-V7) associates with reduced response and overall survival …

A hallmark of prostate cancer progression is dysregulation of lipid metabolism via
overexpression of fatty acid synthase (FASN), a key enzyme in de novo fatty acid synthesis …

Background The androgen receptor splice variant 7 (AR-V7) is associated with resistance to
hormonal therapy in castration-resistant prostate cancer (CRPC). Due to limitations of the …

Despite many recent advances in the therapy for metastatic castration-resistant prostate
cancer (mCRPC), the disease remains incurable, although men suffering from this disease …

Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease,
but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially …

Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development
and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a …

The androgen receptor (AR) signaling axis drives all stages of prostate cancer, including the
lethal, drug-resistant form of the disease termed castration-resistant prostate cancer (CRPC) …